Alembic Pharmaceuticals Limited

NSEI:APLLTD Stock Report

Market Cap: ₹206.0b

Alembic Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Alembic Pharmaceuticals's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 6.8% per year. Alembic Pharmaceuticals's return on equity is 13.2%, and it has net margins of 10.2%.

Key information

-14.7%

Earnings growth rate

-15.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate6.8%
Return on equity13.2%
Net Margin10.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Nov 10
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Sep 25
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Sep 03
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 13
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Jul 20
Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Jun 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

May 11
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Jan 05
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Sep 27
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jun 09
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Apr 13
A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Feb 22
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04
Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20
Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Revenue & Expenses Breakdown

How Alembic Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:APLLTD Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2463,5736,46815,2520
30 Jun 2463,0426,29914,8080
31 Mar 2462,2866,15814,4920
31 Dec 2361,1815,90213,4840
30 Sep 2359,9665,31712,9040
30 Jun 2358,7665,28512,3320
31 Mar 2356,5263,42011,7550
31 Dec 2256,6192,11311,5400
30 Sep 2254,2462,66211,3540
30 Jun 2252,4193,15311,3350
31 Mar 2253,0585,20911,3820
31 Dec 2151,7047,60910,9510
30 Sep 2152,1318,77110,8480
30 Jun 2153,77810,41210,6780
31 Mar 2153,93111,46510,5140
31 Dec 2053,19611,52110,6390
30 Sep 2052,14410,93710,2830
30 Jun 2049,98210,0669,6990
31 Mar 2046,0588,2889,0940
31 Dec 1943,2597,2828,9410
30 Sep 1941,3496,6388,6560
30 Jun 1940,2116,1768,3050
31 Mar 1939,3475,8447,7730
31 Dec 1838,6045,5427,1760
30 Sep 1836,8235,1496,6670
30 Jun 1833,4454,3646,4360
31 Mar 1831,3024,1266,3720
31 Dec 1729,8944,1196,1880
30 Sep 1729,2643,6786,2070
30 Jun 1730,1653,6615,8330
31 Mar 1731,0524,0325,7370
31 Dec 1630,1303,9994,7744,159
30 Sep 1631,5845,8284,6443,693
30 Jun 1632,9427,5154,6483,386
31 Mar 1631,2327,2004,8670
31 Dec 1530,1856,9867,8782,265
30 Sep 1526,0864,9987,4991,869
30 Jun 1521,4692,8817,1281,400
31 Mar 1520,5792,8293,1591,216
31 Dec 1420,1672,7396,4701,223
30 Sep 1419,9062,6926,1841,208
30 Jun 1419,3032,5355,7811,236
31 Mar 1418,6422,3555,4981,164
31 Dec 1317,7702,1794,6891,072

Quality Earnings: APLLTD has high quality earnings.

Growing Profit Margin: APLLTD's current net profit margins (10.2%) are higher than last year (8.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: APLLTD's earnings have declined by 14.7% per year over the past 5 years.

Accelerating Growth: APLLTD's earnings growth over the past year (21.6%) exceeds its 5-year average (-14.7% per year).

Earnings vs Industry: APLLTD earnings growth over the past year (21.6%) exceeded the Pharmaceuticals industry 20%.

Return on Equity

High ROE: APLLTD's Return on Equity (13.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alembic Pharmaceuticals Limited is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sarabjit NangraAngel Broking Private Limited
null nullAntique Stockbroking Ltd.
Vijayaraghavan SwaminathanAvendus Spark